# Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

> **NCT02276963** · PHASE1 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 6 (actual)

## Conditions studied

- Neuromyelitis Optica
- Neuromyelitis Optica Spectrum Disorder

## Interventions

- **DRUG:** Ublituximab

## Key facts

- **NCT ID:** NCT02276963
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2017-07
- **Final completion:** 2019-02-15
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2019-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02276963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02276963, "Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02276963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*